EUCTR2009-016457-18-IT进行中（未招募）不适用
Studio multicentrico, in aperto, a braccio singolo sulla somministrazione ripetuta di QUTENZA per il trattamento del dolore neuropatico periferico Titolo abbreviato: STRIDE - STRIDE
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be included in the clinical trial, subjects must meet all of the following Common Inclusion Criteria and the applicable Population-Specific Inclusion Criteria. Common Inclusion Criteria: 1. Male or female between 18 and 90 years of age, inclusive 2. Be in good health as determined by the investigator 3. Average pain score >=4 during screening period (using the average reported pain from the Brief Pain Inventory [BPI]) 4. Intact, non-irritated, dry skin over the painful area(s) to be treated 5. All females of child bearing potential must be willing to use effective methods of birth control during the study and for 30 days following study termination 6. Be willing and able to comply with protocol requirements for the duration of study participation 7. Subject has given written informed consent Population-specific Inclusion Criteria: All subjects must meet one (and only one) of the Population-Specific Inclusion Criteria for PHN, HIV-AN, PNI or ISNN or have adequately characterized PNP based on clinical history and examination: Postherpetic Neuralgia (PHN) Prior diagnosis of PHN with pain persisting at least 3 months since shingles vesicle crusting, documented by the primary treating physician or investigator Or Painful HIV-Associated Neuropathy (HIV-AN) Presence of HIV-AN existing for a minimum of 3 months, confirmed using the Brief Peripheral Neuropathy Screen (BPNS) at the time of study entry Or Peripheral Neuropathic Injury (PNI) Diagnosis of Post-traumatic Peripheral Neuropathic Pain syndrome, including post-surgical neuropathic pain, neuropathic pain due to peripheral nerve injury, confirmed by a qualified pain specialist and persisting for a minimum of 3 months following the traumatic event Or Idiopathic Small Nerve Neuropathy (ISNN) Diagnosis of ISNN based on clinical criteria, (e.g. quantitative sensory testing) or skin biopsy: Neuropathy exclusively or predominantly affecting A-d (small myelinated) and nociceptive C (unmyelinated) nerve fibres Loss of pinprick and temperature sensation in feet Or Other Peripheral Neuropathic Pain (PNP) Adequately characterized PNP based on clinical history and examination existing at the time of screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects will be excluded from the clinical trial if they meet any of the following Exclusion Criteria: 1.Any prior receipt of QUTENZA open label or blinded study patches 2.Use of oral or transdermal opioids exceeding a total daily dose of morphine of 80 mg/day,or equivalent;or any parenteral opioids,regardless of dose, within 7 days preceding the first patch application visit 3.Lack of an effective pain medication strategy for the subject, such as unwillingness to use opioid analgesics during study treatment, or high tolerance to opioids precluding the ability to relieve treatment-associated discomfort with oxicodone or other analgesic, as judged by the investigator 4.Active substance abuse or history of chronic substance abuse within 1 year prior to enrolment or any prior chronic substance abuse (including alcoholism) likely to re-occur during the study period as judged by the investigator 5.Use of any topical pain medication, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anaesthetics, steroids or capsaicin products on the painful areas within 7 days preceding the first patch application visit 6.Current use of any investigational agent (excluding antiretrovirals in Phase 3 evaluation to treat HIV infection) 7.Unstable or poorly controlled hypertension or a recent history of a cardiovascular event which, in the opinion of the investigator, would put the patient at risk of adverse cardiovascular reactions related to the patch application procedure 8.Evidence of another contributing cause for peripheral neuropathy, and/or treatment within 90 days prior to screening visit with any drug that may have contributed to the sensory neuropathy 9.Past or current history of Type I or Type II diabetes mellitus 10.Current psychotic disorders 11.Clinically significant abnormal ECG at screening 12.Hypersensitivity to capsaicin (i.e., chilli peppers or Over-the-counter [OTC] capsaicin products), any QUTENZA excipients, local anaesthetics, oxycodone, hydrocodone, or adhesives 13.Significant ongoing abnormalities in cardiac, renal, hepatic, or pulmonary function that may interfere either with the ability to complete the study or the evaluation of adverse events 14.Significant pain of an aetiology other than painful HIV-AN, PHN, PNI, ISNN or other adequately characterized PNP, for example; compression-related neuropathies (e.g., spinal stenosis), fibromyalgia or arthritis 15.Posttraumatic neuropathic pain due to Complex Regional Pain Syndrome (CRPS, Type I) 16.Active malignancy or history of malignancy during the past 5 years (a history of squamous cell carcinoma or a basal cell carcinoma not involving the area to be treated is allowed) 17.Evidence of cognitive impairment including dementia that may interfere with subject’s ability to complete study evaluations and recall pain levels in the past 24 hours 18.Planned elective surgery during the trial 19.Neuropathic pain areas located only on the face, above the hairline of the scalp, and/or in proximity to mucous membranes. 20.Female subjects of child-bearing potential with a positive serum or urine pregnancy test prior to treatment
研究者
相似试验
进行中（未招募）
不适用
Estudio abierto multicéntrico, con un único brazo de tratamiento con Pasireotide LAR, en pacientes con tumores poco frecuentes de origen neuroendocrinoSe incluirán los siguientes tumores:1. NETs del páncreasInsulinomaGastrinoma VIPoma Glucagonoma2. NETs pituitariosProlactinoma (PRL)Adenoma pituitario-tirotropo (TSH) Adenoma gonadotropoAdenoma pituitario no funcional (NFPA)3. Tumores ectópicos que secretan ACTH (EAS)4. Síndrome de NelsonMedDRA version: 9.1Level: LLTClassification code 10062476Term: Neuroendocrine tumorEUCTR2008-007348-32-ESovartis Farmaceútica S.A.100
进行中（未招募）
1 期
Phase IV study on right ventricular remodeling in Pulmonary arterial hypertensioPulmonary Arterial HypertensionEUCTR2014-004066-20-ITACTELION PHARMACEUTICALS LTD100
进行中（未招募）
不适用
Ensayo multicéntrico, abierto, con un único brazo de tratamiento y dosis múltiple sobre la eficacia y seguridad de la terapia sustitutiva mensual con factor XIII recombinante (rFXIII) en sujetos con deficiencia congénita de factor XIIIVersión del Protocolo 2 (2008-02-06) y Enmienda relevante 1 versión 2 (2008-04-08). - F13CD-1725Congenital Factor XIII DeficiencyDeficiencia congénita de factor XIIIMedDRA version: 9.1Level: LLTClassification code 10010432Term: Congenital deficiency of other clotting factorsMedDRA version: 9.1Level: LLTClassification code 10061992Term: HaemophiliaMedDRA version: 9.1Level: HLTClassification code 10009735Term: Coagulation disorders congenitalEUCTR2006-003148-51-ESovo Nordisk A/S45
进行中（未招募）
不适用
Ensayo multicéntrico, abierto, con un único brazo de tratamiento y dosis múltiples sobre la seguridad de la terapia sustitutiva mensual con factor XIII recombinante (rFXIII) en sujetos con deficiencia congénita de factor XIIIA Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) inSubjects with Congenital Factor XIII Deficiency(Safety Extension Trial to F13CD-1725)Congenital Factor XIII DeficiencyDeficiencia congénita de factor XIII.MedDRA version: 9.1Level: LLTClassification code 10010432Term: Congenital deficiency of other clotting factorsMedDRA version: 9.1Level: LLTClassification code 10061992Term: HaemophiliaMedDRA version: 9.1Level: HLTClassification code 10009735Term: Coagulation disorders congenitalEUCTR2008-007883-41-ESovo Nordisk A/S40
进行中（未招募）
1 期
Estudio de la administración de Brivaracetam como tratamiento adyuvante en pacientes de 1 mes o más hasta 16 años con epilepsiaocalization-related, generalized or undetermined whether focal orgeneralized epileptic syndrome, according to ILAE classificationSíndrome epiléptico relacionado con localización, generalizado o indeterminado, ya sea focal o generalizado, según la clasificación ILAE.MedDRA version: 13.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2006-006536-22-ESCB Pharma SA100